SeekingAlpha · Feb 9, 2026
Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript
Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call February 9, 2026 3:00 AM ESTCompany ParticipantsTakuya Oyama - Vice President, Chief Financial Officer &...
ES
OTC · ESAIY
Eisai Co., Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic
$7.77
Up+$0.07 (+0.91%)
Updated Aug 22, 2026, 2:11 PM
SID Score
5.1/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 8.46B
- P/E ratio
- 26.05
- Dividend yield
- 3.09%
- 52-week range
- — – —
- Volume
- 45.23K
- Avg. volume
- 101.62K
Price performance
ESAIY price history
1M range · 0 trading sessions · Daily adjusted prices
ESAIY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest ESAIY news
The latest Smart Investors Daily articles mentioning ESAIY.
Stock researchCompany · Overview
ESAIY research
Overview
Company profile and research snapshot.
Company profile
EISAI CO LTD U/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $10.39
- Implied upside
- —
- Analysts
- 18
News briefing
No generated briefing is available yet.
Benzinga · Feb 9, 2026
Reported Sunday, Eisai And Biogen Announce Priority Review Designation In China For Subcutaneous Autoinjector Formulation Of LEQEMBI Lecanemab For Treatment Of Early Alzheimer's Disease
SeekingAlpha · Feb 9, 2026
Eisai Co., Ltd. 2026 Q3 - Results - Earnings Call Presentation
2026-02-09. The following slide deck was published by Eisai Co., Ltd.
Yahoo · Jan 26, 2026
Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to the European Medicines Agency (EMA) for a once every four weeks intravenous (IV) infusion maintenance dosing for lecanemab.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
